Efficacy and Safety between Insulin Glargine Products (LY2963016 and Lantus®) in Patients with T2DM: The ELEMENT 5 Study

被引：0
|
作者：
Pollom, Robyn K.
Lacaya, Lyndon B.
Ilag, Liza L.
机构：
来源：
DIABETES | 2017年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
963-P
引用
收藏
页码：A249 / A249
页数：1
相关论文
共 50 条
  • [1] Similar Efficacy and Safety with LY2963016 Insulin Glargine Compared with Lantus® Insulin Glargine in Patients with T2DM: The ELEMENT 2 Study
    Rosenstock, Julio
    Hollander, Priscilla
    Bhargava, Anuj
    Ilag, Liza
    Pollom, Robyn K.
    Huster, William J.
    Prince, Melvin J.
    DIABETES, 2014, 63 : A17 - A17
  • [2] Similar Efficacy and Safety with LY2963016 Insulin Glargine Compared with Lantus® Insulin Glargine in Patients with T1DM: The ELEMENT 1 Study
    Blevins, Thomas
    Dahl, Dominik
    Rosenstock, Julio
    Ilag, Liza
    Huster, William J.
    Pollom, Robyn K.
    Prince, Melvin J.
    DIABETES, 2014, 63 : A19 - A19
  • [3] Evaluation of Immunogenicity of LY2963016 Insulin Glargine Compared with Lantus® Insulin Glargine in Patients with T1DM or T2DM
    Deeg, Mark
    Ilag, Liza
    Huster, William J.
    Pollom, Robyn K.
    Zielonka, Jason
    Prince, Melvin J.
    Konrad, Robert J.
    DIABETES, 2014, 63 : A19 - A19
  • [4] Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus®) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study
    Blevins, T. C.
    Dahl, D.
    Rosenstock, J.
    Ilag, L. L.
    Huster, W. J.
    Zielonka, J. S.
    Pollom, R. K.
    Prince, M. J.
    DIABETES OBESITY & METABOLISM, 2015, 17 (08): : 726 - 733
  • [5] Similar efficacy and safety with LY2963016 insulin glargine compared with insulin glargine in patients with type 2 diabetes mellitus: the ELEMENT 2 study
    Hollander, P.
    Rosenstock, J.
    Bhargava, A.
    Ilag, L. L.
    Pollom, R. K.
    Huster, W. J.
    Prince, M. J.
    DIABETOLOGIA, 2014, 57 : S388 - S388
  • [6] Duration of Action of 2 Insulin Glargine Products, LY2963016 and Lantus®, in Subjects with Type I Diabetes Mellitus (T1DM)
    Heise, Tim
    Zhang, Xin
    Lam, Eric Chen Quin
    Seger, Mary E.
    Coutant, David
    Chua, Laiyi
    Linnebjerg, Helle
    DIABETES, 2014, 63 : A228 - A228
  • [7] Similar Efficacy and Safety of LY2963016 Insulin Glargine and Insulin Glargine (Lantus®) in Patients with T2D in Age Groups (< 65 Yrs,=65 Yrs)
    Pollom, Robyn K.
    Costigan, Timothy
    Lacaya, Lyndon B.
    Ilag, Liza L.
    Hollander, Priscilla A.
    DIABETES, 2016, 65 : A249 - A249
  • [8] Comparable efficacy and safety between LY2963016 insulin glargine and insulin glargine (Lantus®) in Chinese patients with type 1 diabetes: A phase III, randomized, controlled trial
    Yan, Xiang
    Jiang, Shan
    Lou, Ying
    Zhou, Zhiguang
    DIABETES OBESITY & METABOLISM, 2021, 23 (10): : 2226 - 2233
  • [9] Immunogenicity of LY2963016 insulin glargine and Lantus® insulin glargine in Chinese patients with type 1 or type 2 diabetes mellitus
    Wang, Weimin
    Song, Xiang
    Lou, Ying
    Du, Liying
    Zhu, Dalong
    Zhou, Zhiguang
    DIABETES OBESITY & METABOLISM, 2022, 24 (06): : 1094 - 1104
  • [10] COMPARATIVE PHARMACOKINETICS AND PHARMACODYNAMICS OF 2 INSULIN GLARGINE PRODUCTS, LY2963016 AND LANTUS®, IN HEALTHY SUBJECTS AT 2 DOSE LEVELS
    Zhang, X.
    Lam, E. C. Q.
    Seger, M.
    Coutant, D.
    Chua, L. Y.
    Tan, L. H.
    Soon, D.
    Linnebjerg, H.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2014, 106 : S264 - S264
12345